News · Kira Pharmaceuticals

Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA (January 5, 2023) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield M.D., Ph.D., Chief... Read more

Jan 05, 2023

News · Kira Pharmaceuticals

Kira Pharmaceuticals Announces Clearance to Initiate Phase 2 Evaluation of KP104 in IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) in China and Australia

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (December 20, 2022) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese... Read more

Dec 20, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, MA (November 30, 2022) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2... Read more

Nov 30, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022

Biomarker data demonstrates proof-of-concept for KP104’s dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies... Read more

Nov 03, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals to Present First-in-Human Clinical Data at American Society for Nephrology Kidney Week 2022

Phase 1 biomarker data confirms proof of mechanism with dose-dependent and potent inhibition of alternative and terminal pathways with KP104 via dual-targeting mechanism Data demonstrated KP104 was safe and well tolerated, and supports... Read more

Oct 17, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA for Phase 2 Evaluation of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (October 17, 2022) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today that the Chinese... Read more

Oct 16, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, MA (October 13, 2022) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced participation in the 2nd Annual Needham Biotech... Read more

Oct 13, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Receives FDA Clearance of IND Application for Phase 2 Evaluation of KP104 in Systemic Lupus Erythematosus Associated Thrombotic Microangiopathy (SLE-TMA)

Phase 1 supporting data indicated an encouraging profile and confirmed the dual mechanism of action achieved through targeting both the alternative and terminal complement pathways CAMBRIDGE, MA (October 3, 2022) – Kira Pharmaceuticals, a... Read more

Oct 03, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference

Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration... Read more

Aug 26, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (August 1, 2022) – Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced the... Read more

Aug 01, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (July 28, 2022) – Kira Pharmaceuticals, a global clinical-stage biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that... Read more

Jul 28, 2022

News · Kira Pharmaceuticals

Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (November 16, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the... Read more

Nov 12, 2021

News · Kira Pharmaceuticals

Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China

CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (February 23, 2021)CAMBRIDGE, MA, USA and SUZHOU, JIANGSU, CHINA (February 23, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted... Read more

Feb 22, 2021

News · Kira Pharmaceuticals

Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine

CAMBRIDGE, MA and SUZHOU, JIANGSU (February 2, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, announced today that the first... Read more

Feb 01, 2021

News · Kira Pharmaceuticals

Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA and SUZHOU, China (January 12, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced that Frederick... Read more

Jan 12, 2021

News · Kira Pharmaceuticals

Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies

CAMBRIDGE, MA and SUZHOU, China (January 7, 2021) – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of... Read more

Jan 07, 2021

News · Kira Pharmaceuticals

Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases

– $46M in Financing Secured from Leading Global Life Science Investors – Frederick Beddingfield Appointed as CEO CAMBRIDGE, MA and SUZHOU, China (November 12, 2020) – Kira Pharmaceuticals, a global biotechnology company pioneering a new... Read more

Nov 11, 2020